Stay updated on Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial
Sign up to get notified when there's something new on the Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial page.

Latest updates to the Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4, reflecting a minor version increment for the page documentation.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe Taiwan site address now specifies Taoyuan City instead of Taoyuan, clarifying the city designation for the address while keeping the postal code 33305 the same.SummaryDifference0.0%

- Check29 days agoChange DetectedThe page revision tag was updated from v3.5.2 to v3.5.3, indicating a minor maintenance update to the page. There is no indication of changes to the study content or user-facing information.SummaryDifference0.0%

- Check37 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check58 days agoChange DetectedAdded the keyword Small cell lung carcinoma to the study metadata and included a resources entry for the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to the study content or layout.SummaryDifference0.0%

Stay in the know with updates to Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial page.